Thank you, Roo Roo. I appreciate you clearing this up.One thing...

Thank you, Roo Roo. I appreciate you clearing this up.

One thing I am confused by is the last statement.

"Both drugs function in broad terms as angiogenesis inhibitors and so we view the recent Nexavar data and NDA as a powerful validation for the development of PI-88 in this broad indication."

Powerful validation? First he says that the drugs work "very differently," so it's pretty clear that the mechanism of one will not in any way "validate" the mechanism of the other. If he means to say that a competitor developing a drug for the same market segment is "powerful validation," then I can not help but laugh. A lot.

Here's hoping that PI-88 works, and adds some value to the fight against liver cancer.